Abstract: Embodiments relate to progressively validating access token. In response to intercepting an initial call for a transaction for a service from a client, a token is validated for the initial call of the transaction for the service, the validating including contacting an authentication sever and locally storing a time to live received for the token. In response to intercepting at least one successive call for the transaction for the service from the client, it is determined that the token for the at least one successive call is valid based on the time to live locally saved. The at least one successive call for the transaction for the service is permitted to pass without contacting the authentication sever.

Abstract: Aspects of the invention include determining an event associated with a computing system, the event occurring at a first time, obtaining system data associated with the computing system, determining a system state of the computing system at the first time based on the system data, determining, based on the system state, two or more system data clusters comprising clustered system data associated with the system state of the computing system, determining, via an interpolation algorithm, an interpolated data value for the first time based on the system data, and adjusting the interpolated data value based on a determination that the interpolate data value is outside the two or more system data clusters.

Abstract: Embodiments of the invention are directed to updating a dynamic library. Aspects include receiving an indication that the dynamic library has been updated and identifying all program modules that depend on the dynamic library. Aspects also include, for each program module that depends on the dynamic library, reassigning an application program interface (API) address for a current version of the dynamic library to an API address of the updated version of the dynamic library.

Abstract: Embodiments of the invention include a computer-implemented method that uses a processor to access cryptographic-function constraints associated with an encrypted message. Based on a determination that the cryptographic-function constraints do not include mandatory cryptographic computing resource requirements, first resource-scaling operations are performed that include an analysis of cryptographic metrics associated with a processor. The cryptographic metrics include information associated with the encrypted message, along with performance measurements of cryptographic functions performed by the processor.

Abstract: In an approach for improving data access performance in memory, a processor monitors each data access to a data element in the memory from an application, wherein the application has a plurality of functions. A processor records, during runtime, each data access into a monitoring element table, wherein the record for each data access includes an identity, a start address, an end address, and a memory page number. A processor clusters recorded data accesses for each function based on a distance between data elements accessed in sequence. A processor allocates, based on the data element clustering result, the data elements in a same cluster into a same memory unit in the memory.

Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

Abstract: Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with Axl kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

Abstract: Pyrimidine-2,4-diamines derivatives having activity as JAK2 kinase inhibitors are disclosed, as well as pharmaceutical compositions and methods for using the same in the treatment of cancer and other JAK2 kinase-associated conditions.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.